We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Lena J. Gamble is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
2004 — 2008 |
Gamble, Lena J |
F31Activity Code Description: To provide predoctoral individuals with supervised research training in specified health and health-related areas leading toward the research degree (e.g., Ph.D.). |
Minority Predoctoral Fellowship Program @ Tulane University of Louisiana
DESCRIPTION (provided by applicant): The growth and development of breast tumors is heavily regulated by the activation or repression of growth regulatory genes by steroid hormones. Recently, proteins related to steroid hormone receptors, whose ligands are unknown, have been identified and termed orphan receptors. Our lab has actively explored the role of a new orphan receptor, the retinoid-related orphan receptor-alpha (RORalpha), in breast cancer. The RORalpha subfamily of receptors has been shown to cross-talk with and enhance the activity of the estrogen receptor (ER) and thyroid hormone receptor (TR). Since the ER and TR are known mediators of mitogenic signals in breast cancer cells, the enhancement of their activity by RORalpha should provide an enhanced growth-stimulatory signal to breast cancer cells and recent preliminary studies in our lab support this hypothesis. Our studies also suggest that RORalpha can repress the activity of the retinoic acid receptor (RAR), a potent antimitogenic pathway in breast cancer cells. Based on these studies, we will test the hypothesis that RORalpha crosstalks with other steroid hormone receptors to contribute to the proliferation of breast cancer by regulating the expression of specific growth-modulatory genes in breast cancer cells.
|
1 |